Diagnostic value comparison of the combination of prostate-specific membrane antigen-body PET/MR and the prostate health index with each alone in early diagnosis of prostate cancer
aDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China bDepartment of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China cDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China dShanghai Yuye Medical Technology Co. Ltd, Shanghai, China
Objective: This study aimed to figure out whether the combination of the prostate health index (PHI) and prostate-specific membrane antigen (PSMA)-PET/MR could improve the diagnostic accuracy for prostate cancer (PCa) than that of each individual method used alone.
Methods: In this prospective, observational study, 41 patients who underwent the systematic prostate biopsy between June 2019 and September 2022 were enrolled. Both the PHI test and 18F-PSMA-1007-PET/MR were performed prior to biopsies. The diagnostic accuracy of different models was compared by logistic regression, areas under the curve (AUCs) of the receiver operating characteristic, and net reclassification index (NRI).
Results: Among the 41 patients, 14 (34.1%) were pathologically diagnosed with PCa. The PHI in the PCa group was significantly higher than that in the benign group (44.4 vs. 35.0, p=0.048). Similarly, all the patients in the PCa group received positive results of 18F-PSMA-1007-PET/MR, of which the positive rate was significantly higher than that in benign group (100% vs. 62.96%, p=0.025). The 18F-PSMA-1007-PET/MR provided additional diagnostic values to the PHI (AUC: 0.802 vs. 0.692, p=0.025). However, there was no significant difference between the combination model and the 18F-PSMA-1007-PET/MR alone (AUC 0.802 vs. 0.685, p=0.071). The optimal PHI cutoff of the combination model is 32, with which the model could significantly reduce unnecessary biopsies (NRI: 22.22%, 95% confidence interval: 6.54%-37.90%, p=0.005). However, among patients with the PHI of ≥43.5, there was no significant difference between the combination model and the PHI alone (NRI:11.11%, 95% confidence interval: -0.74%-22.97%, p=0.066).
Conclusion: The combination of the PHI and 18F-PSMA-1007-PET/MR outperforms the PHI alone for predicting PCa, especially in avoiding unnecessary biopsies. However, for patients with the PHI of ≥43.5, the addition of 18F-PSMA-1007-PET/MR to the PHI does not yield additional benefits.
. [J]. Asian Journal of Urology, 2024, 11(4): 555-562.
Jiacheng Liu, Xiaoyi Lin, Da Huang, Miao Zhang, Ao Liu, Xiaohao Ruan, Jingrong Jiang, Hai Huang, Lu Chen, Danfeng Xu. Diagnostic value comparison of the combination of prostate-specific membrane antigen-body PET/MR and the prostate health index with each alone in early diagnosis of prostate cancer. Asian Journal of Urology, 2024, 11(4): 555-562.
Rebecca S, Miller Kd, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67:7-30.
[2]
Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018; 25:524-31.
doi: 10.1111/iju.13593
pmid: 29740894
[3]
Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial. BJU Int 2012; 110:1654-60.
doi: 10.1111/j.1464-410X.2012.11481.x
pmid: 23043563
[4]
Zhang G, Li Y, Li C, Li N, Li Z, Zhou Q. Assessment on clinical value of prostate health index in the diagnosis of prostate cancer. Cancer Med 2019; 8:5089-96.
[5]
Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, et al. A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings. Eur Urol 2019; 75:558-61.
doi: S0302-2838(18)30842-X
pmid: 30396635
[6]
Liu A, Zhang M, Huang H, Zhang C, Ruan X, Lin W, et al. Clinical utility of 18F-PSMA-1007 positron emission tomography/ magnetic resonance imaging in prostate cancer: a singlecenter experience. Front Oncol 2021; 10:612701. https://doi.org/10.3389/fonc.2020.612701.
[7]
Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Ried C, et al. Diagnostic accuracy of 18F-PSMA-1007 PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. J Nucl Med 2021; 62:208-13.
[8]
Zhou Y, Qi W, Cui J, Zhong M, Lv G, Qu S, et al. Construction and comparison of different models in detecting prostate cancer and clinically significant prostate cancer. Front Oncol 2022; 12:911725. https://doi.org/10.3389/fonc.2022.911725.
[9]
Hsieh PF, Li W, Lin W, Chang H, Chang C, Huang C, et al. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population. World J Urol 2020; 38:1207-14.
[10]
Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, et al. Combining prostate health index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int 2018; 121:619-26.
doi: 10.1111/bju.14098
pmid: 29232037
[11]
Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, et al. 68Ga-PSMA positron emission tomography/- computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol 2018; 200:95-103.
[12]
Donato P, Morton A, Yaxley J, Ranasinghe S, Teloken P, Kyle S, et al. 68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is 68Ga-PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imag 2020; 47:1843-51.
[13]
Zhou Y, Fu Q, Shao Z, Qi W, Zhong M, Lv G, et al. The function of prostate health index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study. World J Urol 2023; 41:455-61.
doi: 10.1007/s00345-022-04272-0
pmid: 36592177
[14]
Pencina MJ, D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-72.
doi: 10.1002/sim.2929
pmid: 17569110
[15]
Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/mL: results of a prospective study in a clinical setting. Eur Urol 2011; 60:214-22.
doi: 10.1016/j.eururo.2011.03.052
pmid: 21482022
[16]
Na R, Ye D, Qi J, Liu F, Helfand BT, Brendler CB, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL:r-sults from a multicenter study in China. Prostate 2017; 77:1221-9.
[17]
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol 2021; 80:682-9.
doi: 10.1016/j.eururo.2021.08.002
pmid: 34465492
[18]
Gi Russo, Regis F, Castelli T, Favilla V, Privitera S, Giardina R, et al. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-kallikrein panel score in predicting overall and high-grade prostate cancer. Clin Genitourin Cancer 2017; 15:429-39.e1. https://doi.org/10.1016/j.clgc.2016.12.022.
[19]
Pepe P, Pepe L, Tamburo M, Marletta G, Savoca F, Pennisi M, et al. 68Ga-PSMA PET/CT and prostate cancer diagnosis: which SUVmax value? In Vivo 2023; 37:1318-22.
doi: 10.21873/invivo.13211
pmid: 37103095
[20]
Zhao F, Shen J, Yuan Z, Yu X, Jiang P, Zhong B, et al. Trends in treatment for prostate cancer in China: preliminary patterns of care study in a single institution. J Cancer 2018; 9:1797-803.
doi: 10.7150/jca.25113
pmid: 29805706
[21]
Puhr R, Heinze G, Nold M, Lusa L, Geroldinger A. Firth’s logistic regression with rare events: accurate effect estimates and predictions? Stat Med 2017; 36:2302-17.
[22]
Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, et al. The use of multiparametric magnetic resonance imaging for follow-up of patients included in active surveillance protocol. Can PSA density discriminate patients at different risk of reclassification? Clin Genitourin Cancer 2020; 18:e698-704. https://doi.org/10.1016/j.clgc.2020.04.006.
[23]
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-9.
doi: 10.1016/s0895-4356(96)00236-3
pmid: 8970487
[24]
Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995; 48:1495-501.
doi: 10.1016/0895-4356(95)00510-2
pmid: 8543963
[25]
Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Lechevallier FM, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsynaive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 2019; 20:100-9.
doi: S1470-2045(18)30569-2
pmid: 30470502
Luis G. Medina, Randall A. Lee, Valeria Celis, Veronica Rodriguez, Jaime Poncel, Aref S. Sayegh, Rene Sotelo. Robotic management of urinary fistula[J]. Asian Journal of Urology, 2024, 11(3): 357
-365
.
